Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof
View Patent ↗Methods are provided for treating cancers that have high glucose requirements and that express SGLT2 at levels higher than normal cells, such as metastatic cancers, for example, metastatic lung cancers, employing an SGLT2 inhibitor alone or in combination with a cytotoxic agent and to a composition containing a combination of an SGLT2 inhibitor and a cytotoxic agent.
1. A method for treating cancers that express SGLT2 levels higher than normal cells in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of an SGLT2 inhibitor having the structure
or a prodrug ester thereof, or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein the mammal is a human.
3. The method according to claim 2 wherein the cancer is lung cancer metastatic lesions.
4. The method according to claim 2 wherein the cancer is lung cancer metastatic lesions of the liver.
5. The method according to claim 2 wherein the cancer is lung cancer metastatic lesions of the lymph nodes.
6. The method according to claim 1 wherein the SGLT2 inhibitor has the structure
7. A method for treating cancers that express SGLT2 levels higher than normal cells in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising an SGLT2 inhibitor having the structure
o or a prodrug ester thereof, or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, excipient, or diluent.
8. The method according to claim 7 wherein the mammal is a human.
9. The method according to claim 8 wherein the cancer is lung cancer metastatic lesions.
10. The method according to claim 8 wherein the cancer is lung cancer metastatic lesions of the liver.
11. The method according to claim 8 wherein the cancer is lung cancer metastatic lesions of the lymph nodes.
12. The method according to claim 7 wherein the SGLT2 inhibitor has the structure
13. A method for treating cancers that express SGLT2 levels higher than normal cells in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of an SGLT2 inhibitor having the structure
or a prodrug ester thereof, or a pharmaceutically acceptable salt thereof and a cytotoxic agent where the cytotoxic agent is administered prior to, after, or concurrently with the SGLT2 inhibitor.
14. The method according to claim 13 wherein the mammal is a human.
15. The method according to claim 14 wherein the cancer is lung cancer metastatic lesions.
16. The method according to claim 14 wherein the cancer is lung cancer metastatic lesions of the liver.
17. The method according to claim 14 wherein the cancer is lung cancer metastatic lesions of the lymph nodes.
18. The method according to claim 13 wherein the SGLT2 inhibitor has the structure
19. A method for treating cancers that express SGLT2 levels higher than normal cells in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising an SGLT2 inhibitor having the structure
or a prodrug ester thereof, or a pharmaceutically acceptable salt thereof, a cytotoxic agent and at least one pharmaceutically acceptable carrier, excipient, or diluent.
20. The method according to claim 19 wherein the mammal is a human.
21. The method according to claim 20 wherein the cancer is lung cancer metastatic lesions.
22. The method according to claim 20 wherein the cancer is lung cancer metastatic lesions of the liver.
23. The method according to claim 20 wherein the cancer is lung cancer metastatic lesions of the lymph nodes.
24. The method according to claim 19 wherein the SGLT2 inhibitor has the structure